These findings demonstrate that SSE alleviates PAH by enhancing GPX3-mediated antioxidant defense and suppressing vascular remodeling, supporting its potential as a therapeutic strategy for PAH. The gene discussed is GPX3; the disease is pulmonary arterial hypertension.